

Recaticimab Biosimilar - Research Grade

Product Code: ICH5808

More Information

Species Reactivity: Human

Target: PCSK9^{1/2}

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Recaticimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q8NBP7

Shipping Conditions: Blue ice

background: PCSK9 controls LDL-receptor turnover and remains a central target in cardiovascular and lipid-metabolism research. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of recaticimab, expressed in CHO cells against human PCSK9. Released for research use only, it is purified to a low-endotoxin standard suitable for in vivo studies and supplied in scalable milligram (mg) to gram (g) quantities for high-throughput, heavy-usage laboratories. It is a reliable reagent for PCSK9-blockade assays, receptor-recycling studies, functional readouts, and preclinical models of cholesterol metabolism. Tight quality control makes it a steady reagent for high-throughput pipelines.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks